Stock HEM HEMOSTEMIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hemostemix Inc.

Equities

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 13:57:52 2024-05-03 EDT 		5-day change 1st Jan Change
0.04 CAD 0.00% Intraday chart for Hemostemix Inc. -11.11% -42.86%
04-30 Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-06 Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 24.07 1.504 32.46 9.464 13.63 6.099
Enterprise Value (EV) 1 22.6 3.545 32.38 10.73 17.62 10.26
P/E ratio -3.86 x - -2.91 x -1.46 x -2.41 x -2.31 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - -755,079 x -6,639,112 x -1,611,863 x -5,384,372 x -4,759,325 x
EV / FCF -12.8 x -2.15 x -20 x -10.5 x -4.62 x -9.17 x
FCF Yield -7.83% -46.4% -5.01% -9.48% -21.7% -10.9%
Price to Book 49.3 x - -35.4 x -1.79 x -2.01 x -0.94 x
Nbr of stocks (in thousands) 15,045 15,045 46,369 59,151 75,743 87,122
Reference price 2 1.600 - 0.7000 0.1600 0.1800 0.0700
Announcement Date 19-04-30 20-07-10 21-04-30 22-05-03 23-05-01 24-04-29
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - -4.694 -4.876 -6.655 -3.273 -2.157
EBIT 1 -6.423 -4.696 -4.879 -6.656 -3.274 -2.157
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -6.181 -4.87 -7.768 -6.542 -4.749 -2.502
Net income 1 -6.188 -4.87 -7.768 -6.286 -5.235 -2.502
Net margin - - - - - -
EPS 2 -0.4144 -0.3237 -0.2410 -0.1094 -0.0748 -0.0303
Free Cash Flow 1 -1.771 -1.646 -1.622 -1.017 -3.818 -1.119
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-04-30 20-07-10 21-04-30 22-05-03 23-05-01 24-04-29
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 2.04 - 1.26 3.99 4.17
Net Cash position 1 1.47 - 0.08 - - -
Leverage (Debt/EBITDA) - -0.4346 x - -0.1897 x -1.219 x -1.932 x
Free Cash Flow 1 -1.77 -1.65 -1.62 -1.02 -3.82 -1.12
ROE (net income / shareholders' equity) -232% 274% 302% 197% 86.9% 35.4%
ROA (Net income/ Total Assets) -115% -332% -251% -288% -398% -346%
Assets 1 5.368 1.465 3.092 2.181 1.316 0.723
Book Value Per Share 2 0.0300 -0.2700 -0.0200 -0.0900 -0.0900 -0.0700
Cash Flow per Share 2 0.1000 0 0 0 0 0
Capex - 0.01 - - - -
Capex / Sales - - - - - -
Announcement Date 19-04-30 20-07-10 21-04-30 22-05-03 23-05-01 24-04-29
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
HEMOSTEMIX INC. Stock Hemostemix Inc.
-42.86% 2.55M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+313.59% 8.49B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. HEM Stock
  4. Financials Hemostemix Inc.